Study of treated red blood cells in people with or without antibodies
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests whether red blood cells treated with a special process (INTERCEPT) are safe and work well when given to people who have or don't have antibodies to these treated cells. It aims to understand if the treated cells can be used for transfusions in patients who have developed antibodies from previous transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 4 years old (for children, special rules apply).
- You must have had a blood transfusion in the past.
- If you have antibodies to treated red blood cells, you can join as a 'test' participant; if you don't, you can join as a 'control' participant.
- It must be at least 120 days since your last transfusion of study red blood cells.
- You cannot have active bleeding or be expected to need surgery during the study.
- You must not be taking certain medications that affect red blood cells (like chemotherapy, sulfa drugs, or ribavirin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat donated red blood cells (called INTERCEPT) to see how long they survive in the body and how well they recover. It may help make blood transfusions safer for people who need them.
This study tests a special way to label your own red blood cells so doctors can track how long they survive in your body. It helps improve how we measure blood cell recovery after transfusion.
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
This trial tests whether using a measure of oxygen in your body can guide doctors on when to give you a blood transfusion. It may help avoid unnecessary transfusions while ensuring you get enough oxygen.
This study tests a drug called isatuximab for people who still need red blood cell transfusions after a stem cell transplant from a donor with a different blood type. The drug is an antibody that may help your body start making red blood cells again.
This trial tests whether an allergy medicine (chlorpheniramine) can prevent allergic reactions during blood transfusions. You might be placed in either the medicine group or a placebo (inactive pill) group to compare side effects and reaction rates.
Hear when a new Transfusion Reaction, Hemolytic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.